Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.
Condition(s) studied
Investigational drug(s) / intervention(s)
Data-only evaluation of [18F]FET PET, pituitary MRI, and biomarkers: No study-specific procedures. The study evaluates existing \[18F\]FET PET imaging pituitary MRI, and routine biochemical markers collected as part of standard care.
Study summary
Cushing's disease results from adrenocorticotropic hormone (ACTH) secretion by corticotroph pituitary neuroendocrine tumors (PitNETs). Magnetic resonance imaging (MRI) is the reference modality for etiological diagnosis but may to visualize small corticotroph microadenomas in up to 30% of the cases, and false positives may occur.
The study hypothesis is that positron emission tomography (PET) using \[18F\]fluoroethyl-L-tyrosine (\[18F\]FET) improves localization of ACTH-secreting corticotroph microadenomas compared with MRI and could inform surgical planning and reduce reliance on invasive inferior petrosal sinus sampling.
This observational cohort (retrospective and prospective data) will assess the diagnostic performance of \[18F\]FET PET for tumor localization using postoperative histopathology as the gold standard.
Secondary aims include:
1. assessing cases in which PET modifies localization relative to MRI and is correct by gold standard;
2. inter-reader agreement between two nuclear medicine physicians;
3. correlations between PET signal and biochemical markers of hypercortisolism
4. uni- and multivariable analyses of clinical and imaging parameters influencing PET results;
5. association between PET findings and subsequent biological remission.
Eligibility
Primary outcome measure(s)
- [18F]FET PET Performance for Localizing Corticotroph Pituitary Adenomas — 3 months
Proportion (%) of correct localization of the adenoma by \[18F\]FET PET, using postoperative histopathological examination of the surgical specimen as the reference standard.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hôpital Louis Pradel - Service de Médecine Nucléaire | Bron | France | Recruiting |
More Hospices Civils de Lyon trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07463625 on ClinicalTrials.gov ↗ ← All trials in France